Kelly M Willenberg, MBA, BSN, CHC, CHRC. Kathleen R Hurtado, RPH

Transcription

1 Kelly M Willenberg, MBA, BSN, CHC, CHRC Kathleen R Hurtado, RPH 1 Approach to clinical trial billing monitoring Prioritize the areas of focus Management of non-compliance Communication and training Tools and action plans 2 1

2 Billing for services that have been provided free by the sponsor Billing for services that have been promised free in the Informed Consent Billing for services that are for research-purposes only Billing for services that are part of a nonqualifying clinical trial (this is a complicated issue) Billing for device trials without MAC approval Billing Medicare Advantage Plans for drug studies 3 Clinical trials involve multiple departments in an organization and are typically in silos Billing systems and CTMS systems difficult to integrate Billing systems between hospitals and physicians may be different are they treating the study the same? Lack of coordination of all the study-related details Budgets, contracts, coverage analysis/billing grid Inability to distinguish research subjects and research-related services at the time of visit 4 2

3 Budget and Contract ICF Coverage Analysis Protocol UB s, HCFAs Sponsor Invoices Professional Fees 5 Did I order the CBC on the right account? Did I register the patient when they signed consent? Was that a routine procedure or a research procedure? I can t remember and I don t have time to look. Why do I have to worry about who gets billed anyways? 6 3

4 Few persons in an organization have adequate authority or a thorough awareness of the full process continuum. Budget preparation and negotiation: Who pays for adverse events? What is the language related to subject injury? Informed consent language Are there items promised free of charge? Protocol approval Who pays for additional tests if required by the IRB? Source Documents Physician orders Patient registration Are research visits identified separately from regular visits? Are research charges removed from bills to 3rd party payers? 7 Technological errors: A research flag (i.e., unique study number, a letter on an encounter form, or some other indicator) was not recognized by information systems or was never taken off when patient went off study Human errors: A study number was never placed on the encounter form and/or no one performing charge capture was informed Check-in personnel are unaware of research participants Technicians in ancillary service areas are unaware PI and person negotiating CTA are not in communication. Leads to PI thinking something is billable to payer but it may be for item negotiated for payment from sponsor leading to inadvertent double dipping 8 4

5 Staff time lost on correcting billing errors Lost revenue both on payer side and in research Residual balances Fines and penalties Potential loss of federal grant funding Potential loss of participation in Medicare/Medicaid Enforcement actions and fines Corporate Integrity Agreements Loss of community trust and reputation 9 Risk Based Monitoring 10 5

6 A way to better focus resources A flexible system to track quality according to the needs of the institution Provides the ability to pinpoint quality issues Mechanism for adjusting efforts where they are needed 11 Select Topic Continue Monitoring Choose Criteria Recollect Data Implement Change Risk Based Monitoring Cycle Set Standards Choose Method Plan Change Plan Audit Collect Data 12 6

7 High Priority Registration of research subjects, budget/ca development and approval, charge capture and billing for research services Medium Priority Management of Receivables from Clinical Trials Sponsors and trial evaluation Low Priority Research account establishment 13 High Priority Phase 1 studies, studies with both IP and OP charges, PIs with large volume of studies, habitual offenders, studies with complex/multiple interventions from multiple departments Medium Priority Investigator Initiated Studies Low Priority Studies where sponsor paying all costs 14 7

8 Budget Development and Approval Process is highly distributed and variable Registration of Research Subjects Charge capture/billing for research related services Process for Resolving Billing Inquiries No subject tracking mechanism No system for tracking or reporting Communication and Follow through not done 15 Properly directed, internal audit programs can help an organization stay focused and uncover educational opportunities Clinical trials billing is an area of considerable complexity, uncertainty, and curiosity Move beyond collecting findings to providing insight Collect complaints or feedback from audit program customers Understand the objectives of the stakeholders who own the process being audited Identify and report completed corrective actions Verify improvements and train 16 8

9 An Educational Activity or Moment Promotes Understanding of Errors Found Effectively Uses Resources Raises Standard of Billing Compliance Prompts Change Provides Source of information Is Usually Peer Led 17 Retrospective after billing Advantages: Simple, documentation is complete, refined sample Disadvantages: Processing findings, may not be timely, billing adjustments may be required Prospective before billing Advantages: Timely, avoid billing adjustments Disadvantages: May hold up billing, sample may be limited more difficult to complete 18 9

10 Requiring operation teams self monitor allows greater wider and deeper compliance assurance Stakeholders (CR teams, billing team, IRB, sponsored projects office) working separately cover lots of ground Whenever possible, compare notes to prevent conflict of approaches, to ensure results reach relevant parties Set schedule for collaboration of different primary stakeholders Compliance office(r) should also plan for self-audit Review of audit for completeness Can target hottest spots of audit 19 Institutional self-monitoring begins with risk analysis Identify institutional priorities could be from special concerns Assess system and user groups for weak links Seek agreement of higher administration Select audit elements in relation to risk analysis prepare plan for each sub-set of the audit Consider potential sub-sets: complex studies? easy-tocorrect studies? biggest billers? a particular document/stage of process? a particular department or investigator? Evidence of flawed system? Design audit documents to reflect audit elements *works for compliance office and self-audit ops levels 20 10

11 Once elements of audit are determined and higher administration has agreed, the percentage of X to audit must be determined Generally, audit percentage for adequate representation is minimum of 10% Depending upon resources and volume of studies, more or less may be necessary Some audit elements may not be conducive to representation percentage Flawed system element Audit for cause or special concern 21 Set up schedule of rotation of audit (by department, by doctor, by highest accrual?) Contact study teams and department; provide schedule (and document templates?) o Pre-audit meeting: document request, questions answered o Audit (Was it routine? For cause? Or started with earlier with issue?) o Draft for Discussion Purposed Only with Key Leaders o Corrections due date o Final audit review Final Audit meeting, with corrective action plan for systemic error Follow schedule; follow documents 22 11

12 For identified risk, exposure or noncompliance, possessing the information puts the institution at risk Knowing of non-compliance and not acting to mitigate the event also adds to the risk exposure 23 Understand your institution Risk tolerance Know your research universe All legal entities involved Know how to find all the studies Know how to find all the study-related documents Protocol, CTA/budget, Coverage analysis, Informed Consents, research order forms or alerts, summary of sponsor payment Know how to find all the study subjects Know how to get to all the bills (tech and pro) and the EOBs 24 12

13 Registration Are study subjects identifiable in registration (or scheduling) systems? Is there an easy way for check-in personnel to validate a patient s status as a research participant? Are all points of entry for your facility equipped to deal with various research patient scenarios? Charge Capture Who is pushing the buttons? Do clinicians not associated with the study (i.e., other than the PI, a research nurse, or coordinator) have a simple to understand approach to noting a patient as a research participant? Do lab techs and other non-research personnel have training in how to route research charges or how to identify and route routine test/procedure charges? Billing Is there a way to scrub charges before bills are dropped or prevent over- or inaccurate billing? Is there a bill hold or some other manual, back-end bill review process? What is the time line expectation for reviewing bills on hold and passing them along for final billing by appropriate staff member? 25 Budgeting Is sponsor funding sufficient to cover costs of research? Of start up? Of performing a coverage analysis? Other fees? Who drafts the budget? Where do they get access to charge master rates? Is there a research rate schedule? Is a coverage analysis being performed? Is it crafted using Medicare standards, the NCD, or LCDs? What other medical literature is used to independently determine conventional care? Do sponsor contracts/agreements clearly state which patient care costs are covered? Accounts Receivable Are sponsors being billed and payments being collected (and credited to study accounts) in a timely manner? When sponsors make payments, where do the checks go? Lock box? Who is accountable? Professional Fees Are these being included in study budgets? Being billed at all? Debited against the study budget? 26 13

14 Investigations and Monitoring Does compliance look at residual balances? Could be viewed as kickback or may indicate that non-billable patient care events are not being debited against study accounts PIs sometimes use surplus in a study to fund something else disconnected to the study PIs may use surpluses to fund coordinators on a different study What becomes of funds above a certain threshold? Is a policy in place that defines how surpluses (and deficits) are reconciled? If a deficit, is the PIs department accountable in any way for making up the difference? Does compliance take a sample of studies and a sample of research participants on these studies and trace some bills through the process continuum to identify where (if any) control weaknesses may exist? Finders fees and other incentives Are there conflicts of interest that are incentivizing shady billing practices or leading to cases of non-disclosure of other fees? Training Is there a research compliance curriculum for PIs? Coordinators? Billing personnel? Those who develop coverage analyses? 27 Protocol, CTA, Budget, Coverage Analysis and ALL Amendments All versions of the Informed Consents Confirm anything that was provided by the Sponsor 28 14

15 Select a sample of 2 to 3 research participants for each of the clinical trials selected for testing For each patient, you need: UB-04 (i.e., CMS 1450) CMS 1500 Reimbursement by payer Physician orders Where Do You Start? Verify that the patient received the services per the clinical trial protocol. With the MCA as your guide.. Verify that the charges for each item or service associated with conventional care were posted to the patient account Verify that the charges for each item or service considered research related were posted (or written off) to the research account. 29 The ditty about source documentation works as well for any compliance-assurance process Whatever you do toward compliance-assurance, document the effort Whenever possible, share with others the need for transparent documentation If an audit must be interrupted or truncated, document the reasons why 30 15

16 1. Do Consistent Self Monitoring o Prospective set of data gathered in real time before sent outside (i.e., to a federal payor) where it could be deemed as fraudulent. o Sample size small, non-statistically valid and random 2. Review Results and Consider Remediation Steps o Offer educational moments in response to self monitoring results. Ensure that education is timely, relevant, and specific. Consider use of other practitioners to conduct some of the training (i.e., train the trainer or physician to physicians training). 3. Self Monitoring on a Routine Basis o Consider focus on high risk areas o Set up Routine Self Monitoring Plan Review Results. o Evaluate root cause, target specific practitioners or business/clinical functions that are still out of compliance o Use combinations of classroom training, shadowing, and other one-onone educational options Interventions sometimes necessary! 5. Concurrent Self Monitoring for Consistent Underperformance in Certain Areas o Larger sample, retrospective and prospective o Still probe sample and non-statistically valid o Avoid use of sample sizes that could be extrapolated 32 16

17 The Voluntary Disclosure Protocol states that OIG will not accept a probe sample under 30 claims. The OIG s CIA Guidance for Compliance Programs suggests a probe sample of claims depending on the size of the universe of claims during the sample period. A probe sample size should be determined by a statistician to ensure relevant extrapolation criteria. The OIG s typical Corporate Integrity Agreement threshold for error rate is 5% and in no event greater than 10%. In most cases (but not in all cases) where the error rate exceeds 10%, the OIG often requires that organizations should be prepared to expand the audit to conduct a statistically valid, retrospective, follow up audit at some date in the future. Each of these self monitoring reviews and error rates analyzed should be considered on a case by case basis 33 What Does It Take? 34 17

18 Medicare Secondary Payer/Other Insurance Coverage Place of Service Errors Hospital Outpatient, Ambulatory Surgery Centers Coding of Evaluation and Management Services EHR cookie-cutter medical history Payments for Evaluation and Management Services Evaluation and Management Services during Global Presurgery Periods Excessive Payments for Diagnostic Tests (Medical Necessity) Medicare Billings without research modifiers then research is clearly occurring 35 Identify potential risk areas through monitoring Evaluation and management codes Medical necessity Documentation of referrals Designated health services Whistleblowers Inadequately educated billers Insufficient documentation Use of incorrect codes or no modifiers Coding not supported by the medical record Time records do not support CPT code 36 18

19 How effective are you? Are you asking the right questions? Are you documenting these questions? Are you sought after subject matter expert within organization? Do you step outside of your comfort zone? Internal scorecard for Compliance Feedback from external audits Number/ amounts of re-payments Transparency as an organizational culture 37 Federal Sentencing Guidelines standard 1. the organization exercises due diligence to prevent and detect inappropriate conduct by the Medicare & Medicaid provider; 2. the organization promotes an organizational culture that encourages ethical conduct and is committed to compliance with the law; and 3. the compliance program is reasonably designed, implemented, and enforced so that the program is generally effective in preventing and detecting improper conduct. Failure to prevent or detect specific offenses does not necessarily mean that the program is not generally effective in preventing and detecting such conduct. Federal Sentencing Guidelines amendment effective 11/1/2010 Section 8B2.1(a) 38 19

20 How Do You Implement Action Plan? 39 Where should you start? Since review is done on pre-billing basis, is overpayment of concern? How was the sampling conducted? (one location/ MD or IPA-wide) You know obligations to Medicare and Medicaid, but how should you treat other payers and self-pay? How do you communicate these findings? What does your audit file need to contain? What other remedial actions should be initiated? What other follow-up audits need to be conducted, if any? 40 20

21 Compliance Puzzle What is the Magnitude of the Research Operation? What Do You Need? How many policies are enough? How often does it need to be reviewed? Organizational Chart Governance Job description(s) and reporting Self Monitoring Documentation Financial records retention policy Standardization of the processes 41 Scope of outsourced function(s) Hotline, credentialing, vs. individual audits Considerations Financial constraints Staffing vs. skill set available Space constraints or availability Local vs. Long-distance contractual relationships Contracting Know thy consultant or vendor selection process Contracting under privilege Periodic refreshing of auditors pool 42 21

22 Routine Costs Analysis: Items and Services that are Ordinarily provided to beneficiaries and covered by Medicare Typically provided absent a clinical trial (conventional care) Required solely to administer the investigational drug Provided for the clinically appropriate monitoring of the effects of or prevention of complications from the investigational item Needed to deal with the diagnosis or treatment of complications. Does not include items and services that are: Provided solely to satisfy data collection Provided free of charge. Statutorily excluded or for which there is non-coverage decision. 43 Review credible sources National Guideline Clearinghouse AHRQ / NIH National Comprehensive Cancer Network American College of Cardiology (and others) JAMA, NEJM, etc. Attestation of PI Document the analysis by Medicare Coverage Analysis Use Protocol as foundation Record the services analysis on a billing grid Document the QCT analysis Cite sources CPTs? 44 22

23 Depends on the type of claim Inpatient: No Use V70.7 (i.e., Examination of a participant in a clinical trial) Condition Code 30 only. This indicates that you are working with a qualified clinical trial. When this condition code is reported on a claim, it generally means the service is part of a CMS related clinical trial, demonstration or study Outpatient: Yes-Q1 Routine clinical service provided in a clinical research study that is in an approved clinical research study Use it to identify routine services provided in the trial/study Outpatient: Yes-Q0 Investigational clinical service provided in a clinical research study that is in an approved clinical research study Use it to designate the item under investigation in the trial/study 45 Verify items charged to a payer on UB-04 agree with allowable items per Verify coverage analysis Verify that bills match the revenue that was paid Look for denials Look for partial payments on remittances Calculate excess charges and then calculate excess reimbursement 46 23

24 Look at study accounts vis-à-vis budget High residuals may imply that accountable persons are not consistently debiting study accounts for non-conventional care (i.e., non-billable, research-related activity) High deficits may imply absence of effective planning, low accruals, or other issues Sponsor invoicing is not consistent Cash flow and collections from sponsor is slow Poor planning on budget assumptions Checks from sponsors not being deposited to correct account Too many patient care charges hitting study account and not enough being billed to 3rd party payors You may choose to look in to these sorts of irregularities and conduct a root cause analysis Confirm signed ICF is in medical record Confirm summary of protocol is in medical record 47 Tools to Use 48 24

25 Billing for services paid for by the sponsor Split billing great in theory, not in practice Disconnect between hospital bill and physician bill Lack of reconciliation with sponsor payments Study teams not aware of denials Lack of any type of post-study analysis No communication, coordination and collaboration 49 Sample Audit - Clinical Research Participant Billing - Questions In assessing one s own process for managing clinical trials billing, there are numerous questions to be asked PRIOR to testing/auditing. Operations Financial Management Compliance Management Personnel Operations: Segregation of charges Are billable charges being separated from charges that should be debited against a study/grant account? Who is determining what is billable to 3 rd party payors? PIs? Coordinators? Is this determination objective or subjective? Is there a documented plan that is accessible by those performing charge capture so that they have reference material at this pivotal point in the billing continuum? 50 25

26 Operations: Sample Audit - Clinical Research Participant Billing - Questions Registration Are study subjects identifiable in registration (or scheduling) systems? Is there an easy way for check-in personnel to validate a patient s status as a research participant? Are all points of entry for your facility equipped to deal with research patient scenarios? Charge Capture Do clinicians not associated with the study (i.e., other than the PI, a research nurse, or coordinator) have a simple to understand approach to noting a patient as a research participant? Do lab techs and other non-research personnel have training in how to route research charges or how to identify and route routine test/procedure charges? Billing Is there a way to scrub charges before bills are dropped or prevent over- or inaccurate billing? Is there a bill hold or some other manual, back-end bill review process? What is the time line expectation for reviewing bills on hold and passing them along for final billing by a patient financial services staff member? 51 Sample Audit - Clinical Research Participant Billing - Questions Financial Management: Budgeting Is sponsor funding sufficient to cover costs of research? Of start up? Of performing a coverage analysis? Other fees? Who drafts the budget? Where do they get access to charge master rates? Is there a research rate schedule? Is a coverage analysis being performed in consideration of Medicare standards, the NCD, or LCDs? What other medical literature is used to independently determine conventional care? Do sponsor contracts/agreements clearly state which patient care costs are covered? Accounts Receivable Are sponsors being billed and payments being collected (and credited to study accounts) in a timely manner? When sponsors make payments, where do the checks go? Who is accountable? Professional Fees Are these being included in study budgets? Being billed at all? Debited against the study budget? 52 26

27 Sample Audit -Clinical Research Participant Billing - Questions Personnel: Roles and Responsibilities Who is accountable for what? Does your organization have appropriate controls in place to manage everyone from PIs to check-in personnel? Are the often multiple competing interests and agendas understood? PIs Clinical trials office staff Registration staff Contracting / Tech transfer Medical records & Coding Research finance & Billing Pharmacy, lab, other ancillary services Department administrators Compliance IT staff Counsel Communication Internal Audit Does your organization have a research portal or website with policies, information, downloadable forms, training, and FAQs? Do PIs have a simple way to get information about their studies? Status of study initiation procedures? Financial status of study account? 53 Sample Audit - Clinical Research Participant Billing - Study-level Analysis & Testing What Documents Do You Need?: For each study selected: Study protocol IRB-approved Informed Consent Form Contract or NOGA FDA Status of Investigational Item (IND or IDE) Proposed / Sponsor Budget Coverage Analysis 54 27

28 Sample Audit - Clinical Research Participant Billing - Study-level Analysis & Testing QCT Analysis: Purpose of trial must be the evaluation of an item or service that falls within a Medicare benefit category and is not statutorily excluded. The trial must not be designed exclusively to test toxicity or disease pathophysiology. It must have therapeutic intent. Trials of therapeutic interventions must enroll patients with diagnosed disease rather than healthy volunteers. NOTE: Trials of diagnostic interventions may enroll healthy patients in order to have a proper control group. Trials must be deemed to have desirable characteristics. Funded directly (or indirectly as in a cooperative group) by NIH, CDC, ARHQ, CMS, DOD or VA IND has been reviewed by FDA or has been given exemption 55 Sample Audit - Clinical Research Participant Billing - Study-level Analysis & Testing Routine Costs Analysis: Items and Services that are: Ordinarily provided to beneficiaries and covered by Medicare. Typically provided absent a clinical trial (conventional care). Required solely to administer the investigational drug. Provided for the clinically appropriate monitoring of the effects of or prevention of complications from the investigational item. Needed to deal with the diagnosis or treatment of complications. Does not include items and services that are: Provided solely to satisfy data collection. Provided free of charge. Statutorily excluded or for which there is non-coverage decision

29 But, How Do You Know What Conventional Care Is?: Review credible sources National Guideline Clearinghouse AHRQ / NIH National Comprehensive Cancer Network American College of Cardiology (and others) JAMA, NEJM, etc. Attestation of PI Document the analysis: Sample Audit - Clinical Research Participant Billing - Study-level Analysis & Testing Medicare Coverage Analysis Use Protocol as foundation Record the services analysis on a billing grid Document the QCT analysis Cite sources CPT codes 57 Sample Audit - Clinical Research Participant Billing - Study-level Analysis & Testing Make Sure That You Understand Accountability for Subject Injury: CMS The clinical trial sponsor s agreement with participants that it will pay for medically necessary services related to injuries participants may receive as a result of participation in the trial constitutes a plan or policy of insurance under which payment can reasonably be expected to be made in the event such an injury occurs. [CMS] believes that Medicare would not be the primary payor in such a situation. Correspondence from CMS, Financial Services Group (April 13, 2004) Industry / Sponsor Sponsor pays primary to Medicare if the sponsor is (1) a primary plan, i.e., a liability insurance policy or plan (including self-insurance plans) with (2) a demonstrated responsibility to pay under the MSP laws. Both a liability plan and demonstrated responsibility turn on whether there is liability at issue. A promise to pay for research-related injuries, in and of itself, does not suffice to create liability as that term has been defined by courts. Indeed, a promise to pay may be made to further ethical principles of research and not to discharge a liability

30 Sample Audit - Clinical Research Participant Billing - Study-level Analysis & Testing Medicare as Secondary Payor All or Nothing!! Well, all or half Sponsor agrees to pay for all RRI Site bills sponsor, not payor Site agrees to absorb costs for all RRI Site does not bill sponsor or payor Sponsor agrees to pay for RRI of any federal health care program enrollee Include affirmative provision that Site will not bill FHCP at all Check managed care/commercial agreements for MFN 59 Sample Audit - Clinical Research Participant Billing - Patient-level Analysis & Testing What Documents Do You Need?: Select a sample of 2 to 3 research participants for each of the clinical trials selected for testing. For each patient, you need: UB-04 (i.e., CMS 1450), CMS 1500, EOB, any billing activity On and off study dates Verification whether the participant is a screen failure Signed informed consent Medical Record Where Do You Start?: Verify that the patient received the services per the clinical trial protocol. With the MCA as your guide and orders with medical documentation Verify that the charges for each item or service associated with conventional care were posted to the patient account. Verify that the charges for each item or service considered research related were posted (or written off) to the research account

31 Sample Audit - Clinical Research Participant Billing - Patient-level Analysis & Testing Check Bills for Appropriate Modifiers: The Centers for Medicare & Medicaid Services (CMS) has discontinued the QA (FDA Investigational Device Exemption), QR (Item or Service Provided in a Medicare Specified Study), and QV (Item or Service Provided as Routine Care in a Medicare Qualifying Clinical Trial) HCPCS modifiers as of December 31, Effective for dates of service on and after January 1, 2008, CMS has created the following two new modifiers that will be used solely to differentiate between routine and investigational clinical services: Q0 - Investigational clinical service provided in a clinical research study that is in an approved clinical research study. Q1 Routine clinical service provided in a clinical research study that is in an approved clinical research study. 61 Sample Audit - Clinical Research Participant Billing - Patient-level Analysis & Testing How Do You Know When Modifiers Are Required?: Depends on the type of claim Inpatient: No Use V70.7 (i.e., Examination of a participant in a clinical trial) and, Condition Code 30 only. This indicates that you are working with a qualified clinical trial. When this condition code is reported on a claim, it generally means the service is part of a CMS related clinical trial, demonstration or study. Outpatient: Yes-Q1 Routine clinical service provided in a clinical research study that is in an approved clinical research study. Use it to identify routine services provided in the trial/study Outpatient: Yes-Q0 Investigational clinical service provided in a clinical research study that is in an approved clinical research study. Use it to designate the item under investigation in the trial/study 62 31

32 Sample Audit - Clinical Research Participant Billing - Patient-level Analysis & Testing What Else Should Be Looked At?: For conventional care procedures that are payable by Medicare but performed outside the normal allowable time limit, refer to the ICF to determine if they should be written off or billed to a research participant s payor. Verify items charged to a payor on UB-04 agree with allowable items per the MCA. Verify that bills match the revenue that was paid. Look for denials. Look for partial payments on remittances. Calculate excess charges and calculate excess reimbursement received. Cost Report Research-related costs should not be included in relevant areas of Cost Report. Calculate impact of research-related procedure costs to the Cost Report. 63 Sample Audit - Clinical Research Participant Billing - Patient-level Analysis & Testing Final Step: Look at study accounts vis-à-vis budget High surpluses or residuals may imply that accountable persons are not consistently debiting study accounts for non-conventional care (i.e., non-billable, research-related activity). High deficits may imply absence of effective planning, low accruals, or other issues. Sponsor invoicing is not consistent. Cash flow and collections from sponsor is slow. Poor planning on budget assumptions. Checks from sponsors not being deposited to correct account. Too many patient care charges hitting study account and not enough being billed to 3 rd party payors. May choose to look in to these sorts of irregularities and conduct a root cause analysis. Confirm signed ICF is in medical record. Confirm summary of protocol is in medical record

33 Procedure IRB consent review expected costs section Review Qualifying status of study Identify each item, service or device as routine or research Confirms services are billable under the NCD and all guidelines Documents findings appropriately on Coverage Analysis Verifies consent, budget, contract and Coverage Analysis are congruent Reviews subjects on study Responsibility / Comment Confirms Billing and Charges Against Study to Contract and Budget Verifies Use of Modifiers and Codes on all Medicare Subjects Confirms Medicare Advantage Plans Were Not Billed for Drug Studies 65 Research billing is complex and must be a priority for the institution as a whole Financial and compliance risks must be considered when initiating a clinical trial Quality measures must be taken and reviewed by institution 66 33

34 Kelly M Willenberg kelly@kellywillenberg.com Kathleen Hurtado kathleen@kellywillenberg.com 67 34